In addition, the medtech giant received European Union approval for its Nitron CryoConsole, which builds upon the legacy of the company’s cryo franchise with features to optimize the workflow for cryoballoon ablation.
The news of the regulatory wins in the EU comes about eight months after the medtech giant received a CE mark for its Affera mapping and ablation system, which offers both pulsed field and radiofrequency ablation.
Pulsed-field ablation is a non-thermal method for cardiac ablation that has the potential to positively disrupt the way atrial fibrillation (AFib) is treated. Companies including Medtronic, Boston Scientific, Johnson & Johnson’s Biosense Webster and more are competing to get PFA systems onto the market. Medtronic officials have predicted they’ll be one of the first companies to the U.S. market with a pulsed-field ablation catheter.
“With multiple CE Mark milestones, today’s announcement demonstrates our commitment to innovation and building a strong electrophysiology portfolio,” said Rebecca Seidel, president of the Cardiac Ablation Solutions business, which is part of Medtronic’s Cardiovascular portfolio.
“These milestones are part of our investment in the future of our cryoablation franchise with Nitron, as well as the future of pulsed-field ablation with PulseSelect, following our more than ten years of scientific research and development,” Seidel said in a news release.
Read more about PulseSelect and Nitron CryoConsole in Medtronic’s news release.
